US 12,239,733 B2
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
Dalia Megiddo, Nataf (IL)
Assigned to Seelos Therapeutics, Inc., New York, NY (US)
Filed by Seelos Therapeutics, Inc., New York, NY (US)
Filed on Apr. 5, 2023, as Appl. No. 18/131,161.
Application 18/131,161 is a continuation of application No. 17/355,607, filed on Jun. 23, 2021, abandoned.
Application 17/355,607 is a continuation of application No. 16/951,604, filed on Nov. 18, 2020, abandoned.
Application 16/951,604 is a continuation of application No. 16/460,046, filed on Jul. 2, 2019, granted, now 10,869,831, issued on Dec. 22, 2020.
Application 16/460,046 is a continuation of application No. 14/889,727, granted, now 10,493,023, issued on Dec. 3, 2019, previously published as PCT/IL2014/050411, filed on May 7, 2014.
Claims priority of provisional application 61/820,278, filed on May 7, 2013.
Prior Publication US 2024/0009113 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/7016 (2006.01)
CPC A61K 9/0019 (2013.01) [A61K 9/08 (2013.01); A61K 31/7016 (2013.01)] 18 Claims
 
1. A method for ameliorating a symptom in a subject wherein the subject has spinocerebellar ataxia (SCA) associated with a polyglutamine repeat mutation comprising parenterally administering to said subject a pharmaceutical formulation comprising trehalose as the sole active ingredient;
wherein the concentration of trehalose in said formulation is between about 0.1% (w/v) to about 50% (w/v);
wherein the formulation has an osmolality from about 280 to about 330 mOsm/Kg;
wherein the subject is administered about 10 to about 50 grams of trehalose per week; and
wherein the administration is completed within less than 120 minutes.